Kaye Jack sold $54K of QURE

Kaye Jack sold 1,993 shares of uniQure N.V. (QURE) at $27.06 on 2026-06-11.

Original reporting
SEC EDGAR · Kaye Jack
Published Jun 12, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

Discloses a director’s open-market sale of 1,993 shares at $27.06 on 2026-06-11; no 10b5-1 plan is indicated.

02

Market read

Primarily sentiment/positioning information; not a new fundamental catalyst.

03

What to watch

Traders may over-weight single insider sales; without follow-on buys/sells, volume/price context, or linkage to a broader corporate event, the signal is likely noise.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-12; sale executed 2026-06-11

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

Director Kaye Jack filed an SEC Form 4 selling 1,993 QURE shares in an open-market transaction on 2026-06-11 for ~$53.9K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived unless accompanied by other news.

Evidence & confidence

The filing is a small, open-market sale by a director with no 10b5-1 plan stated; however, insider sales are common and the article provides no new company-specific operational/regulatory catalyst.

Market effects

Minimal; this is company-specific insider transaction data with no sector-wide read-across provided.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could mean the sale was discretionary, but the disclosed size (~$54K) is still small relative to typical market impact.

Key entities

  • Kaye Jack

    Director of uniQure N.V. who sold 1,993 shares via open-market sale.

  • uniQure N.V.

    Company whose shares were sold; insider transaction filed on SEC EDGAR.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREMedAI 8/10

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure N.V. (QURE) shares rose 17.5% in a month, outperforming the industry and S&P 500. The rally was driven by FDA acceptance of its Huntington's disease drug application, ifezuntirgene inilparvovec, for review. Despite weaker Q3 2026 results, investors focus on the drug's potential. QURE's cash position is strong, with $768.4M as of Sept. 30, 2026, expected to fund operations through 2030.

$QUREMedAI 8/10

uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod

uniQure (QURE) is preparing for a potential FDA panel review of its gene therapy AMT-130 for Huntington's disease after receiving a priority review nod. The company presented 48-month data showing treated patients had less functional decline than untreated ones, though control group limitations were noted. uniQure plans a confirmatory study and is preparing for a potential launch, with $780 million in cash to fund operations into 2030.

$QUREHighAI 9/10

Key facts: AMT-130 Priority Review; 48-Month Data; Q3 Revenue +40%

uniQure's AMT-130 was accepted for FDA Priority Review with a decision goal of May 1, 2027. The U.K. validated its marketing application. 48-month data showed slowed Huntington’s disease progression. Q3 2026 revenue rose 40.4% to $5.2 million, below estimates, with net loss narrowing to $61.2 million. Cash reserves were $768.4 million.

MedAI 8/10

uniQure N.V. Q3 2026 Earnings Call Summary

uniQure N.V. reported that the FDA accepted its AMT-130 BLA with priority review for Huntington's disease, citing 36-month data showing a 60% slowing in TFC decline. The company plans a focused commercial launch targeting 15-30 priority institutions. Management expects the confirmatory study to be underway by the 2027 PDUFA date and cash runway to extend into 2030. SG&A expenses increased by $4.5 million year-over-year.

$QUREMed

uniQure (QURE) Q3 2026 Earnings Call Transcript

uniQure (QURE) reported progress in its Q3 2026 earnings call. The company's AMT-130 therapy for Huntington's disease showed a 75% slowing of disease progression in trials. The FDA is reviewing the Biologics License Application (BLA) with a PDUFA date of May 1, 2027. uniQure is preparing for a potential U.S. launch in 2027 and advancing its pipeline, including studies for AMT-260 and AMT-191. The company is also building its commercial teams ahead of the planned launch.